Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

NCT02947867 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

333

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischaemic Central Retinal Vein Occlusion
Neovascular Glaucoma

Interventions

DRUG: aganirsen

Sponsor

Gene Signal SAS

Collaborators

[object Object]
[object Object]
[object Object]